SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (œAltruBio or œthe Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (œAltruBio or œthe Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
ALTB-268 was well tolerated with no serious adverse events across all subject cohorts ALTB-268 demonstrated substantially greater biological activity than first ICE molecule, ALTB-168, enabling...
SAN FRANCISCO, June 15, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (AltruBio or the Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (œAltruBio or œthe Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (€œAltruBio€ or €œthe Company€), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Announces Panels and Presentations at Three March Healthcare Conferences
AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023
SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...